本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2023/5/21 分钟阅读
A Risk-Based Approach to Monitoring of Clinical Investigations-Questions and Answers; Guidance for Industry; Correction
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 12, 2023. The document announced the availability of a final guidance entitled "A Risk-Based Approach to Monitoring of Clinical Investigations--Questions and Answers; Guidance for Industry." The notice of availability for this final guidance was published with an incorrect OMB control number. This document corrects that error.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →